Status: Not yet recruiting
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 25-65Biological sex: AllType: InterventionalSponsor: Akan Biosciences, LLCUpdated: Jan 29, 2025Locations: 1
Eligibility criteria
Adults between the ages of 25-65 years [+8]
Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondy... [+17]